English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/217924
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening

AuthorsAbian, Olga ; Ortega-Alarcon, David; Jiménez-Alesanco, A.; Ceballos-Laita, Laura ; Vega, Sonia; Reyburn, H. T.; Rizzuti, Bruno; Velázquez-Campoy, Adrián
KeywordsSARS-CoV-2 3CL protease
Structural stability
Drug discovery
Issue Date1-Aug-2020
PublisherElsevier BV
CitationInternational Journal of Biological Macromolecules (2020)
AbstractThe global health emergency generated by coronavirus disease 2019 (COVID-19) has prompted the search for preventive and therapeutic treatments for its pathogen, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are many potential targets for drug discovery and development to tackle this disease. One of these targets is the main protease, Mpro or 3CLpro, which is highly conserved among coronaviruses. 3CLpro is an essential player in the viral replication cycle, processing the large viral polyproteins and rendering the individual proteins functional. We report a biophysical characterization of the structural stability and the catalytic activity of 3CLpro from SARS-CoV-2, from which a suitable experimental in vitro molecular screening procedure has been designed. By screening of a small chemical library consisting of about 150 compounds, the natural product quercetin was identified as reasonably potent inhibitor of SARS-CoV-2 3CLpro (Ki ~ 7 μM). Quercetin could be shown to interact with 3CLpro using biophysical techniques and bind to the active site in molecular simulations. Quercetin, with well-known pharmacokinetic and ADMET properties, can be considered as a good candidate for further optimization and development, or repositioned for COVID-19 therapeutic treatment.
Publisher version (URL)https://doi.org/10.1016/j.ijbiomac.2020.07.235
Appears in Collections:(CNB) Artículos
(IQFR) Artículos
(VICYT) Colección Especial COVID-19
Files in This Item:
File Description SizeFormat 
Structural stability_Abian.pdf1,29 MBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.